scout

Acute Myeloid Leukemia: Evolving Perspectives on Testing, Targeted Therapies, and Transplantation

EP. 19: Maintenance Therapy Post-Transplant in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Alexander E. Perl, MD, University of Pennsylvania,Eunice Wang, MD, Roswell Park Comprehensive Cancer Center,Adam Bagg, MD, University of Pennsylvania,Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute

Patient selection for maintenance therapy post-allogeneic transplant in myeloid malignancies and thoughts on treatment of FLT3-mutated disease post-transplant with agents such as midostaurin.

EP. 20: Future Treatment Landscape of AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Alexander E. Perl, MD, University of Pennsylvania,Eunice Wang, MD, Roswell Park Comprehensive Cancer Center,Adam Bagg, MD, University of Pennsylvania,Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute

Corey S. Cutler, MD, MPH, FRCPC; Adam Bagg, MD; Alexander E. Perl, MD, MS; Eunice S. Wang, MD; and Harry P. Erba, MD, PhD, share closing thoughts and emerging therapies on the horizon for the treatment of AML.